{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:30:38Z","timestamp":1773801038325,"version":"3.50.1"},"reference-count":125,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1002\/jcsm.12082","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T10:52:49Z","timestamp":1448621569000},"page":"303-311","source":"Crossref","is-referenced-by-count":86,"title":["Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment"],"prefix":"10.1002","volume":"6","author":[{"given":"Cathleen","family":"Drescher","sequence":"first","affiliation":[{"name":"Innovative Clinical Trials, Department of Cardiology and Pneumology; University Medical Center G\u00f6ttingen (UMG); G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Konishi","sequence":"additional","affiliation":[{"name":"Innovative Clinical Trials, Department of Cardiology and Pneumology; University Medical Center G\u00f6ttingen (UMG); G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Ebner","sequence":"additional","affiliation":[{"name":"Innovative Clinical Trials, Department of Cardiology and Pneumology; University Medical Center G\u00f6ttingen (UMG); G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Springer","sequence":"additional","affiliation":[{"name":"Innovative Clinical Trials, Department of Cardiology and Pneumology; University Medical Center G\u00f6ttingen (UMG); G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"10.1002\/jcsm.12082-BIB0001|jcsm12082-cit-0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-011-0019-5","article-title":"Wasting in chronic kidney disease","volume":"2","author":"Mak","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0002|jcsm12082-cit-0002","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/pgmj.2004.020891","article-title":"Cachexia in malaria and heart failure: therapeutic considerations in clinical practice","volume":"80","author":"Onwuamaegbu","year":"2004","journal-title":"Postgrad Med J"},{"key":"10.1002\/jcsm.12082-BIB0003|jcsm12082-cit-0003","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2008.09.009","article-title":"Cardiac cachexia: a systematic overview","volume":"121","author":"Haehling","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1002\/jcsm.12082-BIB0004|jcsm12082-cit-0004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1002\/jcsm.12082-BIB0005|jcsm12082-cit-0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1002\/jcsm.12082-BIB0006|jcsm12082-cit-0006","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.cger.2011.03.003","article-title":"Sarcopenia: origins and clinical relevance","volume":"27","author":"Rosenberg","year":"2011","journal-title":"Clin Geriatr Med"},{"key":"10.1002\/jcsm.12082-BIB0007|jcsm12082-cit-0007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/gerona\/63.8.829","article-title":"Sarcopenia =\/= dynapenia","volume":"63","author":"Clark","year":"2008","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1002\/jcsm.12082-BIB0008|jcsm12082-cit-0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-014-0135-0","article-title":"Muscle wasting disease: a proposal for a new disease classification","volume":"5","author":"Anker","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0009|jcsm12082-cit-0009","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13539-013-0105-y","article-title":"Cachexia as a major public health problem: frequent, costly, and deadly","volume":"4","author":"Farkas","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0010|jcsm12082-cit-0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphys.2014.00099","article-title":"Skeletal muscle wasting with disuse atrophy is multi-dimensional: the response and interaction of myonuclei, satellite cells and signaling pathways","volume":"5","author":"Brooks","year":"2014","journal-title":"Front Physiol"},{"key":"10.1002\/jcsm.12082-BIB0011|jcsm12082-cit-0011","first-page":"1","article-title":"The wasting continuum in heart failure: from sarcopenia to cachexia","volume":"12","author":"Haehling","year":"2015","journal-title":"Proc Nutr Soc"},{"key":"10.1002\/jcsm.12082-BIB0012|jcsm12082-cit-0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13539-014-0146-x","article-title":"Osteosarcopenic obesity: the role of bone, muscle, and fat on health","volume":"5","author":"Ormsbee","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0013|jcsm12082-cit-0013","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13539-013-0108-8","article-title":"Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patients","volume":"4","author":"Villani","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0014|jcsm12082-cit-0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13539-013-0111-0","article-title":"Why cachexia kills: examining the causality of poor outcomes in wasting conditions","volume":"4","author":"Kalantar-Zadeh","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0015|jcsm12082-cit-0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MCO.0b013e32833862df","article-title":"Signaling pathways perturbing muscle mass","volume":"13","author":"Glass","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1002\/jcsm.12082-BIB0016|jcsm12082-cit-0016","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.2538923","article-title":"A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein","volume":"243","author":"Chau","year":"1989","journal-title":"Science"},{"key":"10.1002\/jcsm.12082-BIB0017|jcsm12082-cit-0017","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.onc.1207390","article-title":"Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases","volume":"23","author":"Marmor","year":"2004","journal-title":"Oncogene"},{"key":"10.1002\/jcsm.12082-BIB0018|jcsm12082-cit-0018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj20040198","article-title":"Getting into position: the catalytic mechanisms of protein ubiquitylation","volume":"379","author":"Passmore","year":"2004","journal-title":"Biochem J"},{"key":"10.1002\/jcsm.12082-BIB0019|jcsm12082-cit-0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/bse0410173","article-title":"The ubiquitin-proteasome system and skeletal muscle wasting","volume":"41","author":"Attaix","year":"2005","journal-title":"Essays Bioche"},{"key":"10.1002\/jcsm.12082-BIB0020|jcsm12082-cit-0020","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1065874","article-title":"Identification of ubiquitin ligases required for skeletal muscle atrophy","volume":"294","author":"Bodine","year":"2001","journal-title":"Science"},{"key":"10.1002\/jcsm.12082-BIB0021|jcsm12082-cit-0021","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.251541198","article-title":"Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy","volume":"98","author":"Gomes","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/jcsm.12082-BIB0022|jcsm12082-cit-0022","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1074\/jbc.M411346200","article-title":"Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase","volume":"280","author":"Tintignac","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1002\/jcsm.12082-BIB0023|jcsm12082-cit-0023","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/emboj.2008.52","article-title":"The initiation factor eIF3-f is a major target for atrogin1\/MAFbx function in skeletal muscle atrophy","volume":"27","author":"Lagirand-Cantaloube","year":"2008","journal-title":"Embo J"},{"key":"10.1002\/jcsm.12082-BIB0024|jcsm12082-cit-0024","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1006\/jmbi.2001.4448","article-title":"Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain","volume":"306","author":"Centner","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1002\/jcsm.12082-BIB0025|jcsm12082-cit-0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1083\/jcb.200108089","article-title":"Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1","volume":"157","author":"McElhinny","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1002\/jcsm.12082-BIB0026|jcsm12082-cit-0026","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1083\/jcb.200901052","article-title":"During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation","volume":"185","author":"Cohen","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1002\/jcsm.12082-BIB0027|jcsm12082-cit-0027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2005.09.068","article-title":"Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin","volume":"354","author":"Kudryashova","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1002\/jcsm.12082-BIB0028|jcsm12082-cit-0028","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gene.2007.08.020","article-title":"FBXO40, a gene encoding a novel muscle-specific F-box protein, is upregulated in denervation-related muscle atrophy","volume":"404","author":"Ye","year":"2007","journal-title":"Gene"},{"key":"10.1002\/jcsm.12082-BIB0029|jcsm12082-cit-0029","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.devcel.2011.09.011","article-title":"The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling","volume":"21","author":"Shi","year":"2011","journal-title":"Dev Cell"},{"key":"10.1002\/jcsm.12082-BIB0030|jcsm12082-cit-0030","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1083\/jcb.201006098","article-title":"Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice","volume":"191","author":"Paul","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1002\/jcsm.12082-BIB0031|jcsm12082-cit-0031","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1172\/JCI200420174","article-title":"Cancer cachexia is regulated by selective targeting of skeletal muscle gene products","volume":"114","author":"Acharyya","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1002\/jcsm.12082-BIB0032|jcsm12082-cit-0032","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","article-title":"Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner","volume":"71","author":"Cosper","year":"2011","journal-title":"Cancer Res"},{"key":"10.1002\/jcsm.12082-BIB0033|jcsm12082-cit-0033","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1054\/bjoc.2001.1696","article-title":"Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia","volume":"84","author":"Costelli","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1002\/jcsm.12082-BIB0034|jcsm12082-cit-0034","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s13539-013-0116-8","article-title":"Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice","volume":"4","author":"Hinch","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle Dec"},{"key":"10.1002\/jcsm.12082-BIB0035|jcsm12082-cit-0035","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur Heart J Apr"},{"key":"10.1002\/jcsm.12082-BIB0036|jcsm12082-cit-0036","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cardiores.2006.10.026","article-title":"Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: Effect on myocardial contractility","volume":"73","author":"Adams","year":"2007","journal-title":"Cardiovasc Res"},{"key":"10.1002\/jcsm.12082-BIB0037|jcsm12082-cit-0037","first-page":"347","article-title":"Cardiac alterations in cancer-induced cachexia in mice","volume":"37","author":"Tian","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1002\/jcsm.12082-BIB0038|jcsm12082-cit-0038","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0304-3835(02)00006-X","article-title":"Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress","volume":"180","author":"Gomes-Marcondes","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1002\/jcsm.12082-BIB0039|jcsm12082-cit-0039","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.febslet.2005.02.017","article-title":"Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats","volume":"579","author":"Barreiro","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1002\/jcsm.12082-BIB0040|jcsm12082-cit-0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2044-5040-2-2","article-title":"TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism","volume":"2","author":"De Larichaudy","year":"2012","journal-title":"Skelet Muscle"},{"key":"10.1002\/jcsm.12082-BIB0041|jcsm12082-cit-0041","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1096\/fj.01-0866com","article-title":"Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy","volume":"16","author":"Hunter","year":"Apr 2002","journal-title":"Faseb J"},{"key":"10.1002\/jcsm.12082-BIB0042|jcsm12082-cit-0042","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","article-title":"IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice","volume":"119","author":"Cai","year":"2004","journal-title":"Cell"},{"key":"10.1002\/jcsm.12082-BIB0043|jcsm12082-cit-0043","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1152\/japplphysiol.01202.2006","article-title":"Oxidative stress and disuse muscle atrophy","volume":"102","author":"Powers","year":"2007","journal-title":"J Appl Physiol (1985)"},{"key":"10.1002\/jcsm.12082-BIB0044|jcsm12082-cit-0044","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0101-7","article-title":"Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia","volume":"4","author":"Der-Torossian","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0045|jcsm12082-cit-0045","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1096\/fj.11-189977","article-title":"Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy","volume":"26","author":"Reed","year":"2012","journal-title":"Faseb J"},{"key":"10.1002\/jcsm.12082-BIB0046|jcsm12082-cit-0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087776","article-title":"C26 cancer-induced muscle wasting is IKKbeta-dependent and NF-kappaB-independent","volume":"9","author":"Cornwell","year":"2014","journal-title":"PLoS One"},{"key":"10.1002\/jcsm.12082-BIB0047|jcsm12082-cit-0047","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1471-2407-12-265","article-title":"Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia","volume":"12","author":"Skorokhod","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1002\/jcsm.12082-BIB0048|jcsm12082-cit-0048","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/emboj.2010.60","article-title":"Mitochondrial fission and remodelling contributes to muscle atrophy","volume":"29","author":"Romanello","year":"2010","journal-title":"Embo J"},{"key":"10.1002\/jcsm.12082-BIB0049|jcsm12082-cit-0049","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13539-012-0073-7","article-title":"Effect of colon cancer and surgical resection on skeletal muscle mitochondrial enzyme activity in colon cancer patients: a pilot study","volume":"4","author":"Phillips","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle Mar"},{"key":"10.1002\/jcsm.12082-BIB0050|jcsm12082-cit-0050","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/j.1600-0838.2009.00900.x","article-title":"Morphological changes in hind limb muscles elicited by adjuvant-induced arthritis of the rat knee","volume":"20","author":"Ozawa","year":"2010","journal-title":"Scand J Med Sci Sports"},{"key":"10.1002\/jcsm.12082-BIB0051|jcsm12082-cit-0051","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2474-10-59","article-title":"Locomotion and muscle mass measures in a murine model of collagen-induced arthritis","volume":"10","author":"Hartog","year":"2009","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1002\/jcsm.12082-BIB0052|jcsm12082-cit-0052","volume-title":"Pathological and Molecular Changes in Skeletal Muscle of Collagen Induced Arthritis","author":"Teixeira","year":"2011"},{"key":"10.1002\/jcsm.12082-BIB0053|jcsm12082-cit-0053","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13539-013-0102-1","article-title":"Temporal development of muscle atrophy in murine model of arthritis is related to disease severity","volume":"4","author":"Filippin","year":"Sep 2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0054|jcsm12082-cit-0054","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2013.10.031","article-title":"Stroke induced Sarcopenia: muscle wasting and disability after stroke","volume":"170","author":"Scherbakov","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1002\/jcsm.12082-BIB0055|jcsm12082-cit-0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13539-013-0103-0","article-title":"Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS)","volume":"4","author":"Knops","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0056|jcsm12082-cit-0056","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1079\/BJN19980085","article-title":"Nutritional status of hospitalized acute stroke patients","volume":"79","author":"Gariballa","year":"1998","journal-title":"Br J Nutr"},{"key":"10.1002\/jcsm.12082-BIB0057|jcsm12082-cit-0057","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archneurol.2007.12","article-title":"Undernutrition as a predictor of poor clinical outcomes in acute ischemic stroke patients","volume":"65","author":"Yoo","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1002\/jcsm.12082-BIB0058|jcsm12082-cit-0058","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000090792","article-title":"Longitudinal changes in muscle strength and mass after acute stroke","volume":"21","author":"Carin-Levy","year":"2006","journal-title":"Cerebrovasc Dis"},{"key":"10.1002\/jcsm.12082-BIB0059|jcsm12082-cit-0059","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S8756-3282(01)00434-3","article-title":"Changes in muscle mass, fat mass, and bone mineral content in the legs after stroke: a 1\u2009year prospective study","volume":"28","author":"Jorgensen","year":"2001","journal-title":"Bone"},{"key":"10.1002\/jcsm.12082-BIB0060|jcsm12082-cit-0060","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1161\/01.STR.0000177878.33559.fe","article-title":"Elevated tumor necrosis factor-alpha in skeletal muscle after stroke","volume":"36","author":"Hafer-Macko","year":"2005","journal-title":"Stroke"},{"key":"10.1002\/jcsm.12082-BIB0061|jcsm12082-cit-0061","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.01.003","article-title":"Elevated visfatin\/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke","volume":"18","author":"Lu","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1002\/jcsm.12082-BIB0062|jcsm12082-cit-0062","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13539-014-0130-5","article-title":"Assessing skeletal muscle mass: historical overview and state of the art","volume":"5","author":"Heymsfield","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0063|jcsm12082-cit-0063","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s13539-012-0081-7","article-title":"Finding good biomarkers for sarcopenia","volume":"3","author":"Scharf","year":"Sep 2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0064|jcsm12082-cit-0064","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s13539-012-0078-2","article-title":"Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia","volume":"3","author":"Cesari","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0065|jcsm12082-cit-0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13539-013-0107-9","article-title":"Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004","volume":"4","author":"Goodman","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0066|jcsm12082-cit-0066","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13539-012-0079-1","article-title":"Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature","volume":"4","author":"Patel","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0067|jcsm12082-cit-0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13539-012-0086-2","article-title":"Serological muscle loss biomarkers: an overview of current concepts and future possibilities","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0068|jcsm12082-cit-0068","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s13539-013-0114-x","article-title":"Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men","volume":"4","author":"Nedergaard","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0069|jcsm12082-cit-0069","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13539-013-0120-z","article-title":"Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults","volume":"5","author":"Fragala","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0070|jcsm12082-cit-0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13539-013-0117-7","article-title":"Isotopic decay of urinary or plasma 3-methylhistidine as a potential biomarker of pathologic skeletal muscle loss","volume":"5","author":"Sheffield-Moore","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0071|jcsm12082-cit-0071","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13539-013-0123-9","article-title":"Abstracts of the 7th Cachexia Conference, Kobe\/Osaka, Japan, December 9-11, 2013","volume":"4","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0072|jcsm12082-cit-0072","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.arr.2015.05.001","article-title":"Sarcopenia-the search for emerging biomarkers","volume":"22","author":"Kalinkovich","year":"2015","journal-title":"Ageing Res Rev"},{"key":"10.1002\/jcsm.12082-BIB0073|jcsm12082-cit-0073","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/1471-2407-14-828","article-title":"Emerging markers of cachexia predict survival in cancer patients","volume":"14","author":"Mondello","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1002\/jcsm.12082-BIB0074|jcsm12082-cit-0074","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jcsm.12005","article-title":"Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrotestinal cancer patients","volume":"6","author":"Stephens","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0075|jcsm12082-cit-0075","first-page":"325","article-title":"The correlation between a chronic inflammatory marker Tartrate-resistant acid phosphatase 5a with cancer cachexia","volume":"20","author":"Wu","year":"2015","journal-title":"J BUON"},{"key":"10.1002\/jcsm.12082-BIB0076|jcsm12082-cit-0076","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0009-8981(02)00026-8","article-title":"Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis","volume":"320","author":"Janckila","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.1002\/jcsm.12082-BIB0077|jcsm12082-cit-0077","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cca.2011.01.035","article-title":"Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease","volume":"412","author":"Janckila","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1002\/jcsm.12082-BIB0078|jcsm12082-cit-0078","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jfma.2012.07.033","article-title":"Tartrate-resistant acid phosphatase 5a in sarcoidosis: further evidence for a novel macrophage biomarker in chronic inflammation","volume":"113","author":"Wu","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"10.1002\/jcsm.12082-BIB0079|jcsm12082-cit-0079","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1152\/japplphysiol.00122.2012","article-title":"Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats","volume":"112","author":"Stimpson","year":"2012","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"10.1002\/jcsm.12082-BIB0080|jcsm12082-cit-0080","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13539-013-0110-1","article-title":"Longitudinal changes in total body creatine pool size and skeletal muscle mass using the D3-creatine dilution method","volume":"4","author":"Stimpson","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0081|jcsm12082-cit-0081","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1210\/jc.2009-1434","article-title":"N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone","volume":"94","author":"Bhasin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/jcsm.12082-BIB0082|jcsm12082-cit-0082","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1073\/pnas.70.9.2687","article-title":"Complete amino-acid sequence of actin of rabbit skeletal muscle","volume":"70","author":"Elzinga","year":"1973","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/jcsm.12082-BIB0083|jcsm12082-cit-0083","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/bi00778a006","article-title":"Amino acid sequence around the single 3-methylhistidine residue in rabbit skeletal muscle myosin","volume":"10","author":"Huszar","year":"1971","journal-title":"Biochemistry"},{"key":"10.1002\/jcsm.12082-BIB0084|jcsm12082-cit-0084","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0026-0495(78)90018-5","article-title":"Musle protein breakdown rates in humans based on Ntau-methylhistidine (3-methylhistidine) content of mixed proteins in skeletal muscle and urinary output of Ntau-methylhistidine","volume":"27","author":"Bilmazes","year":"1978","journal-title":"Metabolism"},{"key":"10.1002\/jcsm.12082-BIB0085|jcsm12082-cit-0085","first-page":"2291","article-title":"Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview","volume":"37","author":"Young","year":"1978","journal-title":"Fed Proc"},{"key":"10.1002\/jcsm.12082-BIB0086|jcsm12082-cit-0086","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13539-014-0136-z","article-title":"Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies","volume":"5","author":"Ebner","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0087|jcsm12082-cit-0087","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12020-012-9836-3","article-title":"Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status","volume":"43","author":"Christensen","year":"2013","journal-title":"Endocrine"},{"key":"10.1002\/jcsm.12082-BIB0088|jcsm12082-cit-0088","doi-asserted-by":"crossref","first-page":"40735","DOI":"10.1074\/jbc.M206379200","article-title":"The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum","volume":"277","author":"Hill","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1002\/jcsm.12082-BIB0089|jcsm12082-cit-0089","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/jcsm.12082-BIB0090|jcsm12082-cit-0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10777","article-title":"A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis","volume":"481","author":"Bostrom","year":"2012","journal-title":"Nature"},{"key":"10.1002\/jcsm.12082-BIB0091|jcsm12082-cit-0091","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-13-0276","article-title":"Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans","volume":"169","author":"Vamvini","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1002\/jcsm.12082-BIB0092|jcsm12082-cit-0092","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","article-title":"Cancer anorexia-cachexia syndrome: current issues in research and management","volume":"52","author":"Inui","year":"Mar-Apr 2002","journal-title":"CA Cancer J Clin"},{"key":"10.1002\/jcsm.12082-BIB0093|jcsm12082-cit-0093","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.mco.0000165004.93707.88","article-title":"Systemic inflammation, cachexia and prognosis in patients with cancer","volume":"8","author":"Deans","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1002\/jcsm.12082-BIB0094|jcsm12082-cit-0094","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1210\/jc.2004-1788","article-title":"Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia","volume":"90","author":"Garcia","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/jcsm.12082-BIB0095|jcsm12082-cit-0095","first-page":"40","article-title":"Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats","volume":"48","author":"Laviano","year":"2000","journal-title":"J Investig Med"},{"key":"10.1002\/jcsm.12082-BIB0096|jcsm12082-cit-0096","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s001090000137","article-title":"Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites","volume":"78","author":"Mantovani","year":"2000","journal-title":"J Mol Med (Berl)"},{"key":"10.1002\/jcsm.12082-BIB0097|jcsm12082-cit-0097","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1210\/jc.2003-031768","article-title":"Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial","volume":"89","author":"Neary","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/jcsm.12082-BIB0098|jcsm12082-cit-0098","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000334106","article-title":"Obestatin: an interesting but controversial gut hormone","volume":"59","author":"Lacquaniti","year":"2011","journal-title":"Ann Nutr Metab"},{"key":"10.1002\/jcsm.12082-BIB0099|jcsm12082-cit-0099","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13539-014-0129-y","article-title":"Abstracts of the 7th Cachexia Conference, Kobe\/Osaka, Japan, December 9-11, 2013 (part 2)","volume":"5","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0100|jcsm12082-cit-0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","article-title":"Cancer cachexia: impact, mechanisms and emerging treatments","volume":"4","author":"Vaughan","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0101|jcsm12082-cit-0101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13539-014-0149-7","article-title":"Are we closer to having drugs to treat muscle wasting disease?","volume":"5","author":"Morley","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0102|jcsm12082-cit-0102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13539-012-0067-5","article-title":"Are there any benefits of exercise training in cancer cachexia?","volume":"3","author":"Argiles","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0103|jcsm12082-cit-0103","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jamda.2013.04.008","article-title":"New strategies for the concurrent strength-, power-, and endurance-training prescription in elderly individuals","volume":"14","author":"Cadore","year":"Aug 2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1002\/jcsm.12082-BIB0104|jcsm12082-cit-0104","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s13539-012-0090-6","article-title":"Research on cachexia, sarcopenia and skeletal muscle in cardiology","volume":"3","author":"Coats","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0105|jcsm12082-cit-0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13539-012-0096-0","article-title":"Cancer cachexia prevention via physical exercise: molecular mechanisms","volume":"4","author":"Gould","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0106|jcsm12082-cit-0106","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jamda.2013.05.015","article-title":"Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis","volume":"14","author":"Silva","year":"Sep 2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1002\/jcsm.12082-BIB0107|jcsm12082-cit-0107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13539-012-0089-z","article-title":"From muscle wasting to sarcopenia and myopenia: update 2012","volume":"3","author":"Haehling","year":"Dec 2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0108|jcsm12082-cit-0108","doi-asserted-by":"crossref","first-page":"569194","DOI":"10.4061\/2011\/569194","article-title":"The effectiveness of exercise interventions for the management of frailty: a systematic review","volume":"2011","author":"Theou","year":"2011","journal-title":"J Aging Res"},{"key":"10.1002\/jcsm.12082-BIB0109|jcsm12082-cit-0109","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s13539-014-0143-0","article-title":"Identifying recreational physical activities associated with muscle quality in men and women aged 50\u2009years and over","volume":"5","author":"Barbat-Artigas","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0110|jcsm12082-cit-0110","doi-asserted-by":"crossref","first-page":"24896","DOI":"10.1074\/jbc.274.35.24896","article-title":"Insulin and exercise decrease glycogen synthase kinase-3 activity by different mechanisms in rat skeletal muscle","volume":"274","author":"Markuns","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1002\/jcsm.12082-BIB0111|jcsm12082-cit-0111","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrd1415","article-title":"GSK3 inhibitors: development and therapeutic potential","volume":"3","author":"Cohen","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/jcsm.12082-BIB0112|jcsm12082-cit-0112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj20031259","article-title":"Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event","volume":"377","author":"Cole","year":"2004","journal-title":"Biochem J"},{"key":"10.1002\/jcsm.12082-BIB0113|jcsm12082-cit-0113","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0092-8674(01)00374-9","article-title":"Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition","volume":"105","author":"Dajani","year":"2001","journal-title":"Cell"},{"key":"10.1002\/jcsm.12082-BIB0114|jcsm12082-cit-0114","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/j.1460-2075.1993.tb05715.x","article-title":"Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation","volume":"12","author":"Hughes","year":"1993","journal-title":"Embo J"},{"key":"10.1002\/jcsm.12082-BIB0115|jcsm12082-cit-0115","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.molcel.2006.10.009","article-title":"A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation","volume":"24","author":"Lochhead","year":"2006","journal-title":"Mol Cell"},{"key":"10.1002\/jcsm.12082-BIB0116|jcsm12082-cit-0116","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"10.1002\/jcsm.12082-BIB0117|jcsm12082-cit-0117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/jcsm.12082-BIB0118|jcsm12082-cit-0118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.phrs.2015.05.010","article-title":"Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action","volume":"99","author":"Dutt","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1002\/jcsm.12082-BIB0119|jcsm12082-cit-0119","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13539-012-0085-3","article-title":"Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model","volume":"4","author":"Lenk","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0120|jcsm12082-cit-0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13539-014-0159-5","article-title":"Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile","volume":"5","author":"Pietra","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0121|jcsm12082-cit-0121","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-013-0125-7","article-title":"The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats","volume":"5","author":"Potsch","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0122|jcsm12082-cit-0122","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13539-011-0046-2","article-title":"The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic\/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design","volume":"2","author":"Stewart Coats","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0123|jcsm12082-cit-0123","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13539-014-0153-y","article-title":"Formoterol in the treatment of experimental cancer cachexia: effects on heart function","volume":"5","author":"Toledo","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0124|jcsm12082-cit-0124","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13539-014-0139-9","article-title":"Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate","volume":"5","author":"Mirza","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1002\/jcsm.12082-BIB0125|jcsm12082-cit-0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2011.02.023","article-title":"Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia","volume":"305","author":"Wang","year":"2011","journal-title":"Cancer Lett"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcsm.12082","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcsm.12082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T10:52:17Z","timestamp":1625309537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.12082"}},"subtitle":["Loss of muscle mass: current developments"],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"URL":"https:\/\/doi.org\/10.1002\/jcsm.12082","archive":["Portico"],"relation":{},"ISSN":["2190-5991"],"issn-type":[{"value":"2190-5991","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}